UPSTREAM BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
UPSTREAM BIO, INC. (UPB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.98% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-11
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.86%, a 10.44% decline year-over-year.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.31%, a 18.73% increase year-over-year.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 3.63%.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.24%, a 24.34% increase from fiscal 2024.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.41%, a 75.77% increase from fiscal 2023.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 1.94%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.98% 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 3.86% 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 4.24% 10-K · filed 2026-03-26 | |||
| 2025-09-30 | 4.25% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 4.27% 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 4.31% 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 3.41% 10-K · filed 2026-03-26 | |||
| 2024-09-30 | 3.35% 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 3.35% 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 3.63% 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 1.94% 10-K · filed 2025-03-12 | |||
| 2023-09-30 | 1.94% 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |